Testing DB-1317 in advanced solid tumors
Part of Cancer clinical trials.
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of solid tumor cancer that has spread or cannot be removed, and standard treatments have stopped working.
- You have not been treated before with a drug that targets ADAM9.
- You have not had a type of targeted chemotherapy called an antibody-drug conjugate with a topoisomerase I inhibitor (like sacituzumab govitecan or trastuzumab deruxtecan).
- You are willing to let doctors look at a stored tumor sample or have a new biopsy (if it is safe).
- Your heart function (LVEF) is at least 50%, and you do not have serious heart disease or unresolved side effects from prior treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
This trial tests a new drug called 7MW4911 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a tumor that expresses a certain protein (CDH17).
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.